Polyrizon signs non– binding loi to expand its innovative intranasal drug delivery platform for psychedelic-based treatments

Raanana, israel, march 14, 2025 (globe newswire) -- polyrizon ltd. (nasdaq: plrz) (the “company” or “polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding letter of intent (loi) with a biotech company focused on psychedelic-derived therapeutics (“the psychedelic company”), to develop a novel intranasal formulation for psychedelic-based treatment applications.
PLRZ Ratings Summary
PLRZ Quant Ranking